The current meta-analysis suggests that the RAGE Gly82Ser polymorphism is associated with an increased risk of CAD and IS, especially in the Chinese population.
Qualified articles had case-control designs and investigated AGER four polymorphisms (T-429C, T-374A, Gly82Ser, G1704A) or circulating soluble RAGE (sRAGE) or endogenous secretory RAGE (esRAGE) levels associated with CAD.
The overall odds ratio (OR) of CAD was 0.99 (95 % CI 0.87-1.13), 1.06 (95 % CI 0.95-1.18) and 1.12 (95 % CI 0.90-1.39) for -374A, -429C, and the minor S allele of the Gly82Serpolymorphism, respectively.
In haplotype analyses, haplotypes C-T-G-G and T-A-G-T (alleles in order of rs1800625, rs1800624, rs2070600 and rs184003), overrepresented in patients, were associated with 52% (95% CI: 1.19-1.87; P = 0.0052) and 63% (95% CI: 1.14-2.34; P = 0.0075) significant increases in adjusted risk for CAD.
The aim of the present study was to investigate the individual and combined effects of receptor for advanced glycation end products (RAGE) -374T/A, RAGE Gly82Ser, and peroxisome proliferator-activated receptor gamma (PPAR-γ) Pro12Ala polymorphisms on the development of coronary artery disease (CAD).
The AGER gene G82S polymorphism was analysed in 270 nondiabetic and 270 type 2 diabetic Chinese Han patients with angiographically proven CAD (luminal stenosis ≥ 50%).
The +557G>A (G82S) showed strong tendency of association with coronary artery disease (coronary artery disease</span> vs. normal; GG: 75.2 vs. 69.8%, GA: 23.2 vs. 28.6%, AA: 1.6 vs. 1.6%, P=0.0524).